{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:28:30Z","timestamp":1787765310196,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara Universitesi","doi-asserted-by":"publisher","award":["FYL-2023-2896"],"award-info":[{"award-number":["FYL-2023-2896"]}],"id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007613","name":"Ankara Universitesi","doi-asserted-by":"publisher","award":["FYL-2023-2896"],"award-info":[{"award-number":["FYL-2023-2896"]}],"id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-11097-8","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:41:04Z","timestamp":1759995664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the IL-6R\/STAT3\/PD-L1 axis: lobaric acid and Tocilizumab as a promising combination immunotherapy in ovarian cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Ibrahim","family":"Gadashli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demet","family":"Cansaran-Duman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"11097_CR1","doi-asserted-by":"crossref","first-page":"12041","DOI":"10.3390\/ijms231912041","volume":"23","author":"R Zhang","year":"2022","unstructured":"Zhang R, Siu MKY, Ngan HYS, Chan KKL (2022) Molecular biomarkers for the early detection of ovarian cancer. Int J Mol Sci 23:12041","journal-title":"Int J Mol Sci"},{"key":"11097_CR2","first-page":"561","volume":"91","author":"SM Penny","year":"2020","unstructured":"Penny SM (2020) Ovarian cancer: an overview. Radiol Technol 91:561\u2013575","journal-title":"Radiol Technol"},{"key":"11097_CR3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jgg.2015.11.002","volume":"43","author":"O Al-Harazi","year":"2016","unstructured":"Al-Harazi O, Al Insaif S, Al-Ajlan MA, Kaya N, Dzimiri N, Colak D (2016) Integrated genomic and network-based analyses of complex diseases and human disease network. J Genet Genomics Yi Chuan Xue Bao 43:349\u2013367","journal-title":"J Genet Genomics Yi Chuan Xue Bao"},{"key":"11097_CR4","doi-asserted-by":"crossref","DOI":"10.1007\/s00005-022-00655-8","volume":"70","author":"N Siminiak","year":"2022","unstructured":"Siminiak N, Czepczy\u0144ski R, Zaborowski MP, I\u017cycki D (2022) Immunotherapy in ovarian cancer. Arch Immunol Ther Exp (Warsz) 70:19","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"11097_CR5","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cvsm.2019.04.010","volume":"49","author":"PJ Bergman","year":"2019","unstructured":"Bergman PJ (2019) Cancer immunotherapies. Vet Clin North Am Small Anim Pract 49:881\u2013902","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"11097_CR6","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.002","volume":"35","author":"M Abbott","year":"2019","unstructured":"Abbott M, Ustoyev Y (2019) Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs 35:150923","journal-title":"Semin Oncol Nurs"},{"key":"11097_CR7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10408360902937809","volume":"46","author":"CN Baxevanis","year":"2009","unstructured":"Baxevanis CN, Perez SA, Papamichail M (2009) Cancer immunotherapy. Crit Rev Clin Lab Sci 46:167\u2013189","journal-title":"Crit Rev Clin Lab Sci"},{"key":"11097_CR8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ (2019) Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov 18:175\u2013196","journal-title":"Nat Rev Drug Discov"},{"key":"11097_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmch.2019.11.001","volume":"59","author":"L K\u00f6tzner","year":"2020","unstructured":"K\u00f6tzner L, Huck B, Garg S, Urbahns K (2020) Small molecules-giant leaps for immuno-oncology. Prog Med Chem 59:1\u201362","journal-title":"Prog Med Chem"},{"key":"11097_CR10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.trecan.2019.05.010","volume":"5","author":"GL Szeto","year":"2019","unstructured":"Szeto GL, Finley SD (2019) Integrative approaches to cancer immunotherapy. Trends Cancer 5:400\u2013410","journal-title":"Trends Cancer"},{"key":"11097_CR11","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.3390\/ijms22126532","volume":"22","author":"S Morand","year":"2021","unstructured":"Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J (2021) Ovarian cancer immunotherapy and personalized medicine. Int J Mol Sci 22:6532","journal-title":"Int J Mol Sci"},{"key":"11097_CR12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"J-H Cha","year":"2019","unstructured":"Cha J-H, Chan L-C, Li C-W, Hsu JL, Hung M-C (2019) Mechanisms controlling PD-L1 expression in cancer. Mol Cell 76:359\u2013370","journal-title":"Mol Cell"},{"key":"11097_CR13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X (2020) Targeting STAT3 in cancer immunotherapy. Mol Cancer 19:145","journal-title":"Mol Cancer"},{"key":"11097_CR14","volume":"11","author":"J Xu","year":"2021","unstructured":"Xu J, Lin H, Wu G, Zhu M, Li M (2021) IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol 11:760971","journal-title":"Front Oncol"},{"key":"11097_CR15","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1002\/anie.201707816","volume":"57","author":"BR Huck","year":"2018","unstructured":"Huck BR, K\u00f6tzner L, Urbahns K (2018) Small molecules drive big improvements in immuno-oncology therapies. Angew Chem Int Ed Engl 57:4412\u20134428","journal-title":"Angew Chem Int Ed Engl"},{"key":"11097_CR16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch C, Barrett D, Teachey DT (2019) Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol 15:813\u2013822","journal-title":"Expert Rev Clin Immunol"},{"key":"11097_CR17","volume":"23","author":"J-M Hong","year":"2018","unstructured":"Hong J-M, Suh S-S, Kim TK, Kim JE, Han SJ, Youn UJ et al (2018) Anti-cancer activity of lobaric acid and Lobarstin extracted from the Antarctic lichen Stereocaulon alpnum. Molecules 23:658","journal-title":"Molecules"},{"key":"11097_CR18","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","volume":"23","author":"BA Inman","year":"2017","unstructured":"Inman BA, Longo TA, Ramalingam S, Harrison MR, Atezolizumab (2017) A PD-L1-Blocking antibody for bladder cancer. Clin Cancer Res Off J Am Assoc Cancer Res 23:1886\u20131890","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"11097_CR19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1055\/a-0777-2420","volume":"85","author":"H-W Lee","year":"2019","unstructured":"Lee H-W, Kim J, Yim J-H, Lee H-K, Pyo S (2019) Anti-inflammatory activity of lobaric acid via suppressing NF-\u03baB\/MAPK pathways or NLRP3 inflammasome activation. Planta Med 85:302\u2013311","journal-title":"Planta Med"},{"key":"11097_CR20","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1016\/j.bmc.2018.10.035","volume":"26","author":"C Carpentier","year":"2018","unstructured":"Carpentier C, Barbeau X, Azelmat J, Vaillancourt K, Grenier D, Lag\u00fce P et al (2018) Lobaric acid and pseudodepsidones inhibit NF-\u03baB signaling pathway by activation of PPAR-\u03b3. Bioorg Med Chem 26:5845\u20135851","journal-title":"Bioorg Med Chem"},{"key":"11097_CR21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.4103\/0973-1482.177218","volume":"14","author":"B Emsen","year":"2018","unstructured":"Emsen B, Aslan A, Turkez H, Joughi A, Kaya A (2018) The anti-cancer efficacies of diffractaic, lobaric, and usnic acid: in vitro inhibition of glioma. J Cancer Res Ther 14:941\u2013951","journal-title":"J Cancer Res Ther"},{"key":"11097_CR22","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673322435240913095954","author":"HA Jama","year":"2025","unstructured":"Jama HA, Ensoy M, Y\u0131lmazer A, Cansaran-Duman D (2025) Delineating the potential therapeutic effects of lobaric acid as a novel strategy in the treatment of melanoma. Curr Med Chem. https:\/\/doi.org\/10.2174\/0109298673322435240913095954","journal-title":"Curr Med Chem"},{"key":"11097_CR23","doi-asserted-by":"crossref","unstructured":"Kerr WG, Chisholm JD (1950) The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves. J Immunol Baltim Md. 2019;202:11\u20139","DOI":"10.4049\/jimmunol.1800991"},{"key":"11097_CR24","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103\u20131115","journal-title":"N Engl J Med"},{"key":"11097_CR25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","volume":"20","author":"V Makker","year":"2019","unstructured":"Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J et al (2019) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20:711\u2013718","journal-title":"Lancet Oncol"},{"key":"11097_CR26","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S et al (2020) Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395:1835\u20131844","journal-title":"Lancet"},{"key":"11097_CR27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/BS9.0000000000000149","volume":"5","author":"Y-J Zhou","year":"2023","unstructured":"Zhou Y-J, Li G, Wang J, Liu M, Wang Z, Song Y et al (2023) PD-L1: expression regulation. Blood Sci 5:77\u201391","journal-title":"Blood Sci"},{"key":"11097_CR28","volume":"124","author":"R Wang","year":"2023","unstructured":"Wang R, Ye H, Yang B, Ao M, Yu X, Wu Y et al (2023) M6A-modified circnfix promotes ovarian cancer progression and immune escape via activating IL-6R\/JAK1\/STAT3 signaling by sponging miR-647. Int Immunopharmacol 124:110879","journal-title":"Int Immunopharmacol"},{"key":"11097_CR29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.2042-7158.1998.tb03312.x","volume":"50","author":"HM Ogmundsd\u00f3ttir","year":"1998","unstructured":"Ogmundsd\u00f3ttir HM, Zo\u00ebga GM, Gissurarson SR, Ing\u00f3lfsd\u00f3ttir K (1998) Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes. J Pharm Pharmacol 50:107\u2013115","journal-title":"J Pharm Pharmacol"},{"key":"11097_CR30","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1055\/s-2004-832657","volume":"70","author":"S Haraldsd\u00f3ttir","year":"2004","unstructured":"Haraldsd\u00f3ttir S, Guolaugsd\u00f3ttir E, Ing\u00f3lfsd\u00f3ttir K, Ogmundsd\u00f3ttir HM (2004) Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro. Planta Med 70:1098\u20131100","journal-title":"Planta Med"},{"key":"11097_CR31","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3389\/fimmu.2019.00867","volume":"10","author":"L Zhang","year":"2019","unstructured":"Zhang L, Chen Y, Li F, Bao L, Liu W (2019) Atezolizumab and bevacizumab attenuate cisplatin resistant ovarian cancer cells progression synergistically via suppressing epithelial-mesenchymal transition. Front Immunol 10:867","journal-title":"Front Immunol"},{"key":"11097_CR32","first-page":"1227","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham A, Atezolizumab (2016) First Global Approval Drugs 76:1227\u20131232","journal-title":"First Global Approval Drugs"},{"key":"11097_CR33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/cancers12020279","volume":"12","author":"S Poschner","year":"2020","unstructured":"Poschner S, Wackerlig J, Castillo-Tong DC, Wolf A, Decken I, von der, Ri\u017ener TL et al (2020) Metabolism of estrogens: turnover differs between Platinum-Sensitive and -Resistant High-Grade serous ovarian cancer cells. Cancers (Basel) 12:279","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11097_CR34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/0008-5472.CAN-20-1674","volume":"81","author":"C Wan","year":"2021","unstructured":"Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S et al (2021) Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in High-Grade serous ovarian cancer. Cancer Res 81(1):158\u2013173","journal-title":"Cancer Res"},{"key":"11097_CR35","volume":"40","author":"C Xie","year":"2021","unstructured":"Xie C, Zhou X, Liang C, Li X, Ge M, Chen Y et al (2021) Apatinib triggers autophagic and apoptotic cell death via VEGFR2\/STAT3\/PD-L1 and ROS\/Nrf2\/p62 signaling in lung cancer. J Exp Clin Cancer Res 40:266","journal-title":"J Exp Clin Cancer Res"},{"key":"11097_CR36","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.7150\/thno.41498","volume":"10","author":"L Tong","year":"2020","unstructured":"Tong L, Li J, Li Q, Wang X, Medikonda R, Zhao T et al (2020) ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics 10:5943\u20135956","journal-title":"Theranostics"},{"key":"11097_CR37","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1038\/onc.2015.466","volume":"35","author":"R Bharti","year":"2016","unstructured":"Bharti R, Dey G, Ojha PK, Rajput S, Jaganathan SK, Sen R et al (2016) Diacerein-mediated inhibition of IL-6\/IL-6R signaling induces apoptotic effects on breast cancer. Oncogene 35:3965\u20133975","journal-title":"Oncogene"},{"key":"11097_CR38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/15376516.2021.1941463","volume":"31","author":"W Cao","year":"2021","unstructured":"Cao W, Zhang Y, Li A, Yu P, Song L, Liang J et al (2021) Curcumin reverses hepatic epithelial mesenchymal transition induced by trichloroethylene by inhibiting IL-6R\/STAT3. Toxicol Mech Methods 31:589\u2013599","journal-title":"Toxicol Mech Methods"},{"key":"11097_CR39","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/mc.22325","volume":"55","author":"N Yanaihara","year":"2016","unstructured":"Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C et al (2016) Antitumor effects of interleukin-6 (IL-6)\/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol Carcinog 55:832\u2013841","journal-title":"Mol Carcinog"},{"key":"11097_CR40","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/ptr.7103","volume":"35","author":"TX Sun","year":"2021","unstructured":"Sun TX, Li MY, Zhang ZH, Wang JY, Xing Y, Ri M et al (2021) Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD-L1 expression and enhancing T-lymphocyte tumor-killing activity. Phytother Res 35:3916\u20133935","journal-title":"Phytother Res"},{"key":"11097_CR41","doi-asserted-by":"crossref","first-page":"72167","DOI":"10.18632\/oncotarget.20050","volume":"8","author":"L Skalniak","year":"2017","unstructured":"Skalniak L, Zak KM, Guzik K, Magiera K, Musielak B, Pachota M et al (2017) Small-molecule inhibitors of PD-1\/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget 8:72167\u201372181","journal-title":"Oncotarget"},{"key":"11097_CR42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2019.10.005","volume":"49","author":"L Yang","year":"2019","unstructured":"Yang L, Lin S, Xu L, Lin J, Zhao C, Huang X (2019) Novel activators and small-molecule inhibitors of STAT3 in cancer. Cytokine Growth Factor Rev 49:10\u201322","journal-title":"Cytokine Growth Factor Rev"},{"key":"11097_CR43","volume":"115","author":"Z Wang","year":"2021","unstructured":"Wang Z, Hui C, Xie Y (2021) Natural STAT3 inhibitors: a mini perspective. Bioorg Chem 115:105169","journal-title":"Bioorg Chem"},{"key":"11097_CR44","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2014.08.039","volume":"147","author":"S Wan","year":"2014","unstructured":"Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G et al (2014) Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147:1393\u20131404","journal-title":"Gastroenterology"},{"key":"11097_CR45","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/carcin\/bgm130","volume":"28","author":"JE Jung","year":"2007","unstructured":"Jung JE, Kim HS, Lee CS, Park D-H, Kim Y-N, Lee M-J et al (2007) Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis 28:1780\u20131787","journal-title":"Carcinogenesis"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11097-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11097-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11097-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T05:04:08Z","timestamp":1766898248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11097-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11097"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11097-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and permission to participate are not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"993"}}